Mini-reviews
Vol. 4 No. 1 (2025)
Unveiling the “common soil” of cardiovascular disease and cancer
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 15 December 2024
Accepted: 27 January 2025
Accepted: 27 January 2025
799
Views
242
Downloads
Authors
The complex relationship between cardiovascular disease (CVD) and cancer has raised significant research interest, supported by growing evidence that these leading causes of morbidity and mortality share several pathogenetic aspects. The “common soil“ hypothesis postulates that CVD and cancer emerge from the same piece of earth as distinct trees, but with intermingled roots, represented by modifiable risk factors and underlying molecular mechanisms. The integration of cardiovascular and cancer prevention through lifestyle and metabolic health improvements represents a necessity, for modern public health. This dual-benefit approach has the potential to reshape how we understand, approach, and ultimately reduce the burden of two of the world's most impactful group of diseases.
Downloads
Download data is not yet available.
Citations
1. Donati MB. The “common soil hypothesis”: evidence from population studies? Thromb Res 2010;125:S92-5. DOI: https://doi.org/10.1016/S0049-3848(10)70023-2
2. Iacoviello L, Santimone I, Latella MC, et al. Nutrigenomics: a case for the common soil between cardiovascular disease and cancer. Genes Nutr 2008;3:19-24. DOI: https://doi.org/10.1007/s12263-008-0079-0
3. Iacoviello L, Bonaccio M, de Gaetano G, Donati MB. Epidemiology of breast cancer, a paradigm of the "common soil" hypothesis. Semin Cancer Biol 2021;72:4-10. DOI: https://doi.org/10.1016/j.semcancer.2020.02.010
4. GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2100-2132. DOI: https://doi.org/10.1016/S0140-6736(24)00367-2
5. Suzuki M, Tomoike H, Dai Z, et al. Polyvascular disease and the incidence of cancer in patients with coronary artery disease. JMA J 2022;5:498-509. DOI: https://doi.org/10.31662/jmaj.2022-0098
6. Strongman H, Gadd S, Matthews A, et al. Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases. Lancet 2019;394:1041-154. DOI: https://doi.org/10.1016/S0140-6736(19)31674-5
7. Hibler EA, Lloyd-Jones DM. Addressing the "common soil" of risk factors for cardiovascular disease and cancer. JACC CardioOncol. 2021;3:59-61. DOI: https://doi.org/10.1016/j.jaccao.2021.02.003
8. Lau ES, Paniagua SM, Liu E, et al. Cardiovascular risk factors are associated with future cancer. JACC CardioOncol. 2021;3:48-58. DOI: https://doi.org/10.1016/j.jaccao.2020.12.003
9. Kaneko H, Suzuki Y, Ueno K, et al. Association of Life's Simple 7 with incident cardiovascular disease in 53 974 patients with cancer. Eur J Prev Cardiol. 2022;29:2324-32. DOI: https://doi.org/10.1093/eurjpc/zwac195
10. Narayan V, Thompson EW, Demissei B, et al. Mechanistic biomarkers informative of both cancer and cardiovascular disease: JACC state-of-the-art review. J Am Coll Cardiol 2020;75:2726-37. DOI: https://doi.org/10.1016/j.jacc.2020.03.067
11. Wilcox NS, Amit U, Reibel JB, et al. Cardiovascular disease and cancer: shared risk factors and mechanisms. Nat Rev Cardiol. 2024;21:617-631. DOI: https://doi.org/10.1038/s41569-024-01017-x
12. Pounis G, Bonaccio M, Di Castelnuovo A, et al. Polyphenol intake is associated with low-grade inflammation, using a novel data analysis from the Moli-sani study. Thromb Haemost 2016;115:344-52. DOI: https://doi.org/10.1160/th15-06-0487
13. Bonaccio M, Di Castelnuovo A, Pounis G, et al. A score of low-grade inflammation and risk of mortality: prospective findings from the Moli-sani study. Haematologica 2016;101:1434-41. DOI: https://doi.org/10.3324/haematol.2016.144055
14. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 2017;390:1833-42. DOI: https://doi.org/10.1016/S0140-6736(17)32247-X
15. Crawley DJ, Holmberg L, Melvin JC, et al. Serum glucose and risk of cancer: a meta-analysis. BMC Cancer 2014;14:985. DOI: https://doi.org/10.1186/1471-2407-14-985
16. Jeong IK, Oh DH, Park SJ, et al. Inhibition of NF-κB prevents high glucose-induced proliferation and plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Exp Mol Med 2011;43:684-92. DOI: https://doi.org/10.3858/emm.2011.43.12.079
17. Placencio VR, DeClerck YA. Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Res 2015;75:2969-74. DOI: https://doi.org/10.1158/0008-5472.CAN-15-0876
18. Iacoviello L, Agnoli C, De Curtis A, et al. Type 1 plasminogen activator inhibitor as a common risk factor for cancer and ischaemic vascular disease: the EPICOR study. BMJ Open 2013;3:e003725. DOI: https://doi.org/10.1136/bmjopen-2013-003725
19. Costanzo S, Parisi R, De Curtis A, et al. Tissue Plasminogen activator levels and risk of breast cancer in a case-cohort study on Italian women: results from the Moli-sani study. Thromb Haemost 2021;121:449-56. DOI: https://doi.org/10.1055/s-0040-1718531
20. Parisi R, Panzera T, Russo L, et al. Fibrinogen levels in relation to colorectal cancer onset: A nested case-cohort study from the Moli-sani cohort. Front Cardiovasc Med 2022;9:1009926. DOI: https://doi.org/10.3389/fcvm.2022.1009926
21. Iacoviello L, de Laat-Kremers R, Costanzo S, et al. Low antithrombin levels are associated with low risk of cardiovascular death but are a risk factor for cancer mortality. PLoS One 2022;17:e0271663. DOI: https://doi.org/10.1371/journal.pone.0271663
22. Parisi R, Costanzo S, de Laat-Kremers R, et al. Plasma fibrinogen levels and all-cause and cause-specific mortality in an Italian adult population: results from the Moli-sani study. Bleeding Thromb Vasc Biol 2023;2:46. DOI: https://doi.org/10.4081/btvb.2023.46
23. Simes J, Robledo KP, White HD, et al. D-dimer predicts long-term cause-specific mortality, cardiovascular events, and cancer in patients with stable coronary heart disease: LIPID study. Circulation 2018;138:712-23. DOI: https://doi.org/10.1161/CIRCULATIONAHA.117.029901
How to Cite
1.
Iacoviello L, Donati MB. Unveiling the “common soil” of cardiovascular disease and cancer. Bleeding Thromb Vascul Biol [Internet]. 2025 Feb. 24 [cited 2025 Sep. 30];4(1). Available from: https://www.btvb.org/btvb/article/view/167
Copyright (c) 2025 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Marwa Eltemamy, Robert Namushi, Narayanamoorthi Saravanan, Importance of assessment of carotid plaques in the managementof acute ischemic stroke: floating intracarotid plaque , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 3 (2023)
- Ronda Lun, Deborah M. Siegal, Cancer-associated ischemic stroke: current knowledge and future directions , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Gary E. Raskob, Risk of recurrent venous thromboembolism in cancer patients after discontinuation of anticoagulant therapy , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Ang Li, Emily Zhou, Trends and updates on the epidemiology of cancer-associated thrombosis: a systematic review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz, Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth, Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Francesca Santilli, Paola Simeone, Rossella Liani, Inflammation, platelets and diabetes , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 2 (2023)
- Nadim Tawil, Lata Adnani, Janusz Rak, Coagulome and tumor microenvironment: impact of oncogenes, cellular heterogeneity and extracellular vesicles , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
- Francesco Cicconi, Ankle brachial index for the diagnosis of asymptomatic lower extremity peripheral arterial disease , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Maria J. Fernandez Turizo, Rushad Patell, Jeffrey I. Zwicker, Identifying novel biomarkers using proteomics to predict cancer-associated thrombosis , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024)
You may also start an advanced similarity search for this article.
